Three drug indications for patients with peripheral arterial disease bite the dust: report from the American Heart Association meeting 2007 in Orlando.
Powell
J T
JT
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D000572:American Heart Association; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D006801:Humans; D008790:Metoprolol / Q000009:adverse effects*; D016491:Peripheral Vascular Diseases / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D011804:Quinolines / Q000009:adverse effects*; D012294:Rifamycins / Q000009:adverse effects*; D014481:United States
D000319:Adrenergic beta-Antagonists; D000900:Anti-Bacterial Agents; D000924:Anticholesteremic Agents; D011804:Quinolines; D012294:Rifamycins; C068980:KRM 1648; C483909:torcetrapib; D008790:Metoprolol